CpG Oligodeoxynucleotide-Coupled B Cells for Selective SLE Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for systemic lupus erythematosus (SLE) targeting B cells are limited in effectively inhibiting pathologically activated B lymphocytes in both circulation and lymphatic organs while preserving humoral immune function, leading to incomplete clinical benefits and side effects like infections due to B cell deficiency.

Innovation Solution

Development of non-methylated CpG oligodeoxynucleotides, such as ODN 1826 and ODN 4084-F, covalently coupled to B lymphocytes via alpha-1,3-fucosyltransferase to form stable glycosidic bonds, allowing targeted recognition and inhibition of activated B cells without activating the MyD88/NF-κB signaling pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If B cell clearance therapy or B cell activation inhibition is used, then circulating B cells are effectively removed, but B cells in lymphoid nodes remain active and humoral immune function is compromised

Engineering Contradiction:

Improveinhibition of pathologically activated B lymphocytesVSAvoidhumoral immunodeficiency and infections

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by differentiating the inhibition mechanism based on B cell location. TLR9 agonist ODNs are used to specifically activate and inhibit pathologically activated B cells in lymphoid nodes, while preserving normal B cell function in circulation. This localized approach allows selective inhibition of disease-causing B cells without compromising overall humoral immunity.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses TLR9 agonist ODNs as intermediary substances that mediate the inhibition of B cell activation. These ODNs bind to TLR9 receptors on B cells, triggering a signaling pathway that inhibits pathogenic B cell activity without directly removing or destroying the cells, thus preserving humoral immune function while eliminating harmful B cell responses.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If TLR9 agonist CpG ODN is used to activate B cells, then humoral immunity is enhanced, but autoimmune response and tissue damage increase

Engineering Contradiction:

Improveproduction of immunoglobulin and cytokinesVSAvoidautoimmune tissue damage

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent inverts the traditional use of TLR9 agonists. Instead of using CpG ODNs to activate B cells and enhance immunity (which causes autoimmune damage), the patent uses the same TLR9 pathway to inhibit pathologically activated B cells. By activating TLR9 on already-activated B cells, the pathway is inverted to produce inhibitory effects rather than stimulatory effects, thereby reducing autoimmune tissue damage.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent converts the harmful effect of TLR9 activation (which normally causes autoimmune responses) into a beneficial inhibitory effect. By using TLR9 agonist ODNs to activate TLR9 on pathologically activated B cells, the previously harmful autoimmune response is transformed into a beneficial mechanism that inhibits B cell activation and reduces tissue damage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Object-affected harmful factors

If B cell deficiency is induced to inhibit autoimmune response, then autoimmune damage is reduced, but infections due to humoral immunodeficiency occur

Engineering Contradiction:

Improveautoimmune tissue damageVSAvoidinfections from humoral immunodeficiency

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The coupled oligodeoxynucleotides effectively inhibit pathologically activated B lymphocytes, reducing side effects and enhancing therapeutic efficacy by preserving B cell function and ensuring site-specific migration to diseased lymphoid organs.

Implementation Method 1

covalently coupled to B lymphocytes via alpha-1,3-fucosyltransferase to form stable glycosidic bonds

Methodology Applied

Scientific EffectGlycosidic bond formation: Chemical Bonding

Data Source

PatentEP4703473A1Non-methylated cpg oligodeoxynucleotide and application thereof

Publication Date: 2026.03.04 RAY MEDICINE BIOTECHNOLOGY CO LTD

Figure 1
Figure 2
Figure 3

AI summary

The present invention provides a non-methylated cytosine-phosphate-guanine dinucleotide oligodeoxynucleotide and a B lymphocyte coupled thereto, the B lymphocyte can target and migrate to the diseased lymphoid organs and inhibit the B lymphocytes activated under pathological conditions, and has a targeted therapeutic effect on pathological damage caused by B lymphocyte activation.